Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Gonsalves W, Devarakonda S, Baz R, Neparidze N, Adjei A, Kunos C, Kumar S. Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Blood 2019, 134: 3160. DOI: 10.1182/blood-2019-123399.Peer-Reviewed Original ResearchMitochondrial respirationNormal protein homeostasisProteasome inhibitorsTricarboxylic acid cycleProtein homeostasisProteotoxic stressC-myc activationCellular bioenergeticsGenomic DNATCA cycleMolecular strategiesCellular respirationAcid cycleCell deathGlutamine metabolismImmunoglobulin proteinGlutaminase inhibitorMM cellsProteasome inhibitionIncrease of glutamineResistance mechanismsCell linesCancer cellsCB-839Human myeloma cell lines